middle.news

How Cleo Diagnostics Is Poised to Transform Ovarian Cancer Detection by 2026

3:01pm on Friday 31st of October, 2025 AEDT Healthcare
Read Story

How Cleo Diagnostics Is Poised to Transform Ovarian Cancer Detection by 2026

3:01pm on Friday 31st of October, 2025 AEDT
Key Points
  • Constructive second pre-submission meeting with U.S. FDA
  • Acquisition of ~1,600 biobank samples for test refinement
  • Health economic study underway to support U.S. reimbursement
  • U.S. clinical trial recruitment on track for Q1 2026 completion
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Cleo Diagnostics (ASX:COV)
OPEN ARTICLE